NVS241220C125000
- 0.15
- 0.000.00%
Novartis AG Newsroom
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Swiss Equities an Overweight Pick Next Year -- Market Talk
Top Gap Ups and Downs on Wednesday: MLI, MSTR, GSK and More
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Announces Target Price $125
Monte Rosa Closes Global License Agreement With Novartis
Barclays Sticks to Its Sell Rating for Novartis AG (NOVN)
Raymond James, Cantor Bullish on UniQure Following FDA Update
Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment
Deutsche Bank Sticks to Their Hold Rating for Novartis AG (NOVN)
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
On Saturday, Novartis Announced Longer-term Results From Phase 3 ASC4FIRST Trial Of Scemblix (Asciminib) Compared To Standard-Of-Care Tyrosine Kinase Inhibitors And Imatinib Alone In Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia
Top Gap Ups and Downs on Friday: CNQ, EQNR, LULU and More
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Express News | Reuters Agriculture & Energy Policy Reporter Leah Douglas Posts On X "SCOOP: The USDA Is Issuing a Federal Order Mandating the National Milk Supply Be Tested for Bird Flu. Testing Will Begin Dec. 16 in Six States: CA, CO, MI, MS, PA, OR. Bird Flu Has...
Wells Fargo's 'Core' List: GOOGL, DIS, HD, WMT, and More!
The Max Foundation (Max) Expands Collaboration With Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Novartis's Fabhalta Trial Success Supports Sales Target -- Market Talk
Express News | Novartis Announced Topline Results From The APPULSE-PNH Phase 3B Study Of Twice-daily Oral Monotherapy Fabhalta (Iptacopan) In Paroxysmal Nocturnal Hemoglobinuria Patients Who Were Switched From Anti-C5 Therapies, After 24 Weeks Of Treatment With...
Novartis' Rare Blood Disorder Drug Improves Hemoglobin Levels in Phase 3b Trial
Kepler Capital Reaffirms Their Buy Rating on Novartis AG (NOVN)